Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
